March 24 (Reuters) - India's drug regulator has tightened surveillance against the unauthorised sale and promotion of ...

Top medical experts in India are sounding the alarm over the misuse of GLP-1 drugs like Ozempic for lifestyle weight loss, ...

Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.

Cheap GLP-1 drugs like semaglutide are now available in India. Experts explain benefits, risks, side effects and who should actually use these weight-loss injections ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.

India’s drug regulator has intensified checks on GLP-1 weight-loss drugs like semaglutide, targeting illegal sales, ...

The Indian government announced on March 24 that it has intensified regulatory surveillance to combat the unauthorized sale ...

India's health ministry has issued a warning over the unregulated use of generic GLP-1 weight-loss drugs like semaglutide, as ...

How the rush to release affordable and accessible versions of weight loss drugs could reshape the fight against ‘diabesity’ ...

The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20.

India's drug regulator tightened surveillance against unauthorized sale and promotion of weight-loss drugs, the country's ...